Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.71 |
| ▸ | DRD4 | P21917 | 5/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139670 | 1.00 | RORC (0.71) | RORCDRD4BACE1CNR2MEN1 | |
| SCHEMBL20139629 | 0.83 | RORC (1.00) | RORCMEN1KMT2A | |
| SCHEMBL20139637 | 0.83 | RORC (1.00) | RORCMEN1KMT2A | |
| SCHEMBL23951506 | 0.81 | RORC (0.51) | RORCDRD4 | |
| SCHEMBL23924367 | 0.81 | RORC (0.51) | RORCDRD4 | |
| SCHEMBL23924365 | 0.81 | RORC (0.51) | RORCDRD4 | |
| SCHEMBL29900609 | 0.81 | RORC (0.51) | RORCDRD4 | |
| SCHEMBL2197505 | 0.75 | RORC (0.68) | RORC | |
| SCHEMBL23683607 | 0.75 | RORC (0.72) | RORCDRD4BACE1CCR5 | |
| SCHEMBL23683614 | 0.75 | RORC (0.72) | RORCDRD4BACE1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3538522-A1 | ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089406-A1 | ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | RORB, RORC, RORA | RORC 2/4885DRD4 3550/4885BACE1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.